Cell Article: Single Genetic Locus Linked To Top Cancer-Targeted Biochemical Pathways

November 27, 1997

MEMPHIS, Tenn., November 28, 1997 -- While identifying a new cancer-fighting tumor suppressor gene called ARF, scientists at St. Jude Children's Research Hospital have made another, potentially more far-reaching discovery, that a single genetic locus called INK4a encodes protein products that regulate the most frequently targeted biochemical pathways in human cancers, regardless of patient age, tumor site or type.

The findings, likely to have major implications for the development of anti-cancer therapies, appear in today's issue of Cell.

Pivotal in one of the pathways is the newly identified tumor suppressor ARF. The St. Jude researchers found that ARF interacts with one of the most frequently mutated tumor suppressor genes in human cancer, p53. Tumor suppression by ARF in mice could not occur if p53, which causes cells with defective DNA to arrest their growth and to self-destruct, is itself defective, missing, or otherwise nonfunctional.

The interdepartmental St. Jude research team led by Charles J. Sherr, M.D., Ph.D., an investigator of the Howard Hughes Medical Institute, had earlier found ARF embedded in INK4a. "This economical, overlapping organization of both the ARF and INK4a genes in the same chromosomal location, observed in both mice and humans, is not seen anywhere else in mammals," explained Sherr.

The other cancer-related biochemical pathway, previously discovered, involves a protein separately encoded by INK4a that affects the activity of another tumor suppressor, the retinoblastoma protein, RB.

"What is most surprising," said Sherr, "is that a single genetic locus, INK4a/ARF, encodes two different products that regulate the two biochemical pathways involving p53 and RB." Mutations and deletions that adversely affect the INK4a/ARF locus are very common in different forms of human cancer.

Sherr and his team confirmed ARF as a tumor suppressor by finding that, when ARF is eliminated or knocked-out in mice, the mice develop cancers. At two months of age, mice deprived of ARF began to develop cancer spontaneously and, by six months, a third exhibited malignant tumors. Treating the mice with a known carcinogen or with X-rays hastened the onset of tumors. Conversely, mouse cell lines missing the protein encoded by ARF promptly stopped proliferating when the ARF protein was reintroduced in the cells via a retroviral vector.

Although the exact mechanism by which ARF exerts its antiproliferative effects on cells is unknown, ARF may operate, like p53, through another cell growth inhibitor called p21Cip1 , which is found at increased levels in the presence of ARF.

St. Jude Children's Research Hospital, in Memphis, Tenn, was founded by the late entertainer Danny Thomas. The hospital is an internationally recognized biomedical research center dedicated to finding cures for catastrophic diseases of childhood. The hospital's work is primarily supported through funds raised by the American Lebanese Syrian Associated Charities (ALSAC). All St. Jude patients are treated regardless of their ability to pay. ALSAC covers all costs of treatment beyond those reimbursed by third party insurers, and total costs for families who have no insurance.

St. Jude Children's Research Hospital

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.